NCT07917910Not yet recruitingPhase 2
A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB)
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of HT-101 Injection in Combination With HT-102 Injection in Participants With Chronic Hepatitis B (CHB) Virus Infection
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
Phase II trial of HT-101 + HT-102 in CHB: (1) functional cure in treatment-naïve patients (vs placebo); (2) efficacy of sequential interferon in previously treated patients.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 29 Oct 2026
- Start date
- 30 Oct 2026
- Primary completion date
- 30 Oct 2028
- Lead sponsor
- Suzhou HepaThera Biotech Co., Ltd.
- Diseases
- Hepatitis B
- NCT number
- NCT07917910
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 120
- From 30 Oct 2026 to the primary completion date, 30 Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of cirrhosis, or evidence suggesting significant hepatic fibrosis or cirrhosis;
- Individuals who have experienced major trauma or undergone major surgery within 3 months prior to screening, or who plan to undergo major surgery during the study period;
- Previous history of solid organ transplantation or hematopoietic stem cell transplantation (HSCT);
- Known allergy to any component of the investigational product and/or other products of the same class, or history of severe food or drug allergy, or allergic constitution;
Other illness
- History of hepatocellular carcinoma (HCC) or suspected HCC;
Other
- Pregnant or lactating women, or those with a positive pregnancy test;
- Participants deemed by the investigator, for any other reason, to be unsuitable to participate in this study;
Who the study is looking for
- Having a full understanding of the nature, significance, possible benefits, and risks of this study, demonstrating good compliance, and voluntarily signing the Informed Consent Form (ICF)；
- Treatment-naïve participants clinically diagnosed with chronic Hepatitis B virus (HBV) infection;
- Male or female participants of childbearing potential (WOCBP) must commit to having no plans for procreation, sperm or ovum donation during the study and for 6 months after the last dose, and must voluntarily use a highly effective contraceptive method.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.